BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces that a securities class action lawsuit has been filed on behalf of all persons or entities who purchased the common stock of Medivation, Inc. (“Medivation” or the “Company”) (Nasdaq:MDVN) between July 17, 2008 and March 2, 2010, inclusive (the “Class Period”). The class action lawsuit was filed in the United States District Court for the Northern District of California.
Medivation is a biopharmaceutical company focused on the development of small molecule drugs for the treatment of Alzheimer’s disease, Huntington’s disease, and castration-resistant prostate cancer. Its product pipeline includes Dimebon, a drug being developed as a treatment for mild-to-moderate Alzheimer’s disease. The Complaint alleges that the defendants violated federal securities laws by issuing material misrepresentations to the market concerning Medivation’s operations and prospects, thereby artificially inflating the price of the Company’s securities.
No class has yet been certified in the above action. Until a class is certified, you are not represented by counsel unless you retain one. If you purchased Medivation, Inc. common stock between July 17, 2008 and March 2, 2010, you have certain rights, and have until May 10, 2010, to move for Lead Plaintiff status. To be a member of the class you need not take any action at this time, and you may retain counsel of your choice. If you wish to discuss this action or have any questions concerning this Notice or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020, by telephone at (215)638-4847, Toll-Free at (888)638-4847, by email to firstname.lastname@example.org or visit our website at www.howardsmithlaw.com.